Hydrocortison Fairmed Healthcare (Hydrocortisone)

Hydrocortison Fairmed Healthcare is indicated for systemic management of inflammatory and autoimmune disorders where glucocorticoid therapy is appropriate. It may be considered in conditions that require oral corticosteroid treatment under physician guidance.

• Acute exacerbations of asthma or chronic obstructive pulmonary disease.
• Severe allergic reactions such as anaphylaxis when other measures are insufficient.
• Autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus.
• Adrenal insufficiency or cortisol deficiency requiring replacement therapy.
• Certain dermatologic or gastrointestinal inflammatory conditions unresponsive to topical therapy.

• Hydrocortisone binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and interacts with glucocorticoid response elements on DNA. This modulates transcription of multiple genes, leading to decreased synthesis of pro‑inflammatory cytokines, prostaglandins, and leukotrienes, while increasing anti‑inflammatory proteins such as annexin‑1. The overall effect reduces inflammation and suppresses immune cell activation. It also influences carbohydrate metabolism and vascular tone, contributing to systemic glucocorticoid activity.

Oral hydrocortisone may cause a range of adverse reactions, varying from mild and transient to potentially serious.

Common

• Increased appetite leading to modest weight gain.
• Fluid retention that may cause mild peripheral edema.
• Elevated blood glucose levels, particularly in patients with diabetes.
• Mood alterations such as irritability, anxiety, or difficulty sleeping.
• Skin thinning and easy bruising, especially on the arms and legs.
• Gastrointestinal discomfort, including nausea or increased risk of ulcer formation.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal axis, which can precipitate an adrenal crisis during stress.
• Severe infections due to immunosuppression, including opportunistic bacterial, viral, or fungal pathogens.
• Osteoporosis or increased risk of bone fractures with prolonged therapy.
• Psychiatric disturbances such as depression, mood swings, or rare psychotic episodes.

When prescribing oral hydrocortisone, clinicians consider several precautionary measures to minimize risks and ensure safe use.

• Assess baseline blood pressure, glucose, and electrolyte status before initiating therapy.
• Use the lowest effective dose for the shortest duration required.
• Monitor for signs of adrenal insufficiency during dose tapering or discontinuation.
• Caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
• Avoid abrupt cessation after prolonged use to prevent withdrawal symptoms.
• Evaluate bone health periodically, especially in long‑term treatment.

Hydrocortisone can interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid

• Concurrent use with strong CYP3A4 inducers such as rifampin, which may reduce hydrocortisone plasma levels.
• Co‑administration with systemic antifungal agents like ketoconazole that inhibit cortisol metabolism, potentially causing excess glucocorticoid activity.
• Combining with other systemic glucocorticoids, leading to additive immunosuppression and heightened side‑effect risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration.
• Anticoagulants such as warfarin can have altered efficacy, requiring closer monitoring of INR.
• Vaccines, especially live attenuated types, may have reduced effectiveness or increased infection risk.